AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23900032
Drug: Nonlinguistic cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonlinguistic cognitive processing treatment
Trial: 23900032
Drug: English treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: English treatment
Trial: 23900032
Drug: Bilingual (Spanish-English)
RxNorm normalized name: Nitroglycerin Lingual Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilingual (Spanish-English) treatment
Trial: 12612143
Drug: SPE chips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPE chips and spread group (17 g/d SPE)
Trial: 12612143
Drug: SPE spread
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPE spread (10 g/d SPE)
Trial: 12612143
Drug: SPE chips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPE chips (7 g/d SPE)
Trial: 10690834
Drug: Near confluent
RxNorm normalized name: Albatrellus confluens fruiting body extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Near confluent laser treatment
Trial: 10690834
Drug: Less dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less dense treatment
Trial: 3720569
Drug: Special intervention
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special intervention (diuretic use)
Trial: 30340813
Drug: Cranberry functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry functional beverage (CFB), 750 ml daily for 8 weeks
Trial: 22453675
Drug: Lichtenstein repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lichtenstein repair with lightweight polypropylene mesh (L group)
Trial: 20400496
Drug: Meals with
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meals with 250 to 3000 kcal containing 500 mg of calcium
Trial: 8674787
Drug: Roxithromycin (ROM)
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (ROM) administered for 8 weeks
Trial: 1839759
Drug: Teicoplanin 15
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 15 mg/kg
Trial: 1839759
Drug: Teicoplanin 20
RxNorm normalized name: Teicoplanin 200 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 20 mg/kg
Trial: 1839759
Drug: Teicoplanin 25
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 25 mg/kg
Trial: 6636790
Drug: Inderal 40
RxNorm normalized name: Inderal 40mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderal 40 mg
Trial: 6636790
Drug: Inderal 40
RxNorm normalized name: Inderal 40mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderal 40 mg (in soldiers with anxiety and high pulse)
Trial: 31447129
Drug: Intravenous fixed-dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fixed-dose combination (FDC) of ibuprofen 300 mg + acetaminophen 1000 mg
Trial: 30126463
Drug: Mobile fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile fresh fruit and vegetable (F&V) markets plus nutrition education (e.g. campaigns, DVDs, newsletters, recipes, and chef demonstrations)
Trial: 26575696
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops
Trial: 26575696
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops (SLIT3 subgroup)
Trial: 26575696
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops (SLIT1 and SLIT2 subgroups)
Trial: 26575696
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with oral antihistamines
Trial: 25155941
Drug: Acceptance‐Enhanced Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance‐Enhanced Behavior Therapy for Trichotillomania
Trial: 20963638
Drug: Chemotherapy (ifosfamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (ifosfamide, DTIC, and doxorubicin administered in 14-day intervals supported by G-CSF on days 5-13)
Trial: 20963638
Drug: Chemotherapy (ifosfamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (ifosfamide, DTIC, and doxorubicin)
Trial: 17351950
Drug: Oral gefitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gefitinib 250 mg daily (G arm)
Trial: 17351950
Drug: Vinorelbine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 15 mg/m2 as an intravenous infusion on Day 1 and oral gefitinib 250 mg daily on Days 2 through 14 every 2 weeks (GV arm)
Trial: 16278618
Drug: E(2) 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2) 0.25 mg
Trial: 16278618
Drug: E(2) 1
RxNorm normalized name: vitamin E 1 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2) 1 mg
Trial: 16278618
Drug: E(2) 2
RxNorm normalized name: (E)-2-butenedioic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2) 2 mg/NETA 1 mg
Trial: 16278618
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (all E(2) groups)
Trial: 11932567
Drug: Acustat electro‐membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acustat electro‐membrane microcurrent therapy
Trial: 7620745
Drug: Morning light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning light treatment (8.00-8.30 a.m., n = 14)
Trial: 7620745
Drug: Afternoon light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afternoon light treatment (1.00-1.30 p.m., n = 15)
Trial: 7620745
Drug: Evening light
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening light treatment (8.00-8.30 p.m., n = 12)
Trial: 7620745
Drug: Morning light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning light treatment followed by evening light (n = 13)
Trial: 7620745
Drug: Evening light
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening light treatment followed by morning light (n = 14)
Trial: 2371420
Drug: Healthy subjects
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects using the roadside alcolmeter at flow rates of 10 l min‐1 and 40 l min‐1
Trial: 7318359
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg by mouth)
Trial: 29219095
Drug: Compliance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance with any combination of two guidelines
Trial: 25595104
Drug: Alkalinized solution
RxNorm normalized name: ALKALINE AROMATIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinized solution (lidocaine 1% and epinephrine in sodium bicarbonate 1.4%)
Trial: 25595104
Drug: Standard solution
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard solution (lidocaine 1% and epinephrine in saline 0.9%)
Trial: 22748702
Drug: Apremilast 10
RxNorm normalized name: apremilast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 10 mg twice daily
Trial: 17504124
Drug: Molecular targeted
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular targeted drugs (e.g., Glivec/Imatinib)
Trial: 17504124
Drug: Chemotherapy drugs
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy drugs
Trial: 10100270
Drug: Ondansetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (5 mg/m2 30 min before chemotherapy, then 4 mg/m2 every 8 h i.v.)
Trial: 10100270
Drug: Tropisetron (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (0.2 mg/kg 30 min before chemotherapy, max dose 5 mg)
Trial: 8092559
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate 200 micrograms once daily
Trial: 1853146
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole once daily (maintenance treatment)
Trial: 1853146
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine twice daily (maintenance treatment)
Trial: 29428426
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (Pylera)
Trial: 29428426
Drug: 14-days sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-days sequential therapy
Trial: 26949703
Drug: BNP (0.005 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP (0.005 μg/kg/min before contrast media exposure and saline hydration)
Trial: 23018437
Drug: AS03A‐adjuvanted H1N1v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03A‐adjuvanted H1N1v vaccine (3.75 μg haemagglutinin)
Trial: 23018437
Drug: Nonadjuvanted H1N1v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted H1N1v vaccine (15 μg haemagglutinin)
Trial: 23018437
Drug: AS03A‐adjuvanted H1N1v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03A‐adjuvanted H1N1v vaccine
Trial: 12911461
Drug: NMDA-antagonist memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMDA-antagonist memantine
Trial: 6731261
Drug: Propranolol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.2 mg/kg)
Trial: 12754030
Drug: Topical vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical vancomycin (500mg)
Trial: 11003358
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg on day 0 and day 4 posttransplantation)
Trial: 1448311
Drug: Oral rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rifampin (20 mg/kg/day for 4 days)
Trial: 21357819
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy with a defibrillator (CRT-D) in patients with LBBB
Trial: 21357819
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy with a defibrillator (CRT-D) in patients with non-LBBB
Trial: 19663668
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid therapy
Trial: 11772140
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (25, 50, 75, and 100 microg/h, replaced every 3 days)
Trial: 10223542
Drug: IFN‐alpha2b (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha2b (3 MU three times weekly, intramuscularly)
Trial: 2204343
Drug: Enciprazine (D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enciprazine (D 13 112), dosage not specified
Trial: 2204343
Drug: Enciprazine (D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enciprazine (D 13 112), highest dosage
Trial: 28301282
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg hepatitis B vaccine (IM20 group)
Trial: 28301282
Drug: 60 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg hepatitis B vaccine (IM60 group)
Trial: 21492926
Drug: 360 days
RxNorm normalized name: LUVISET 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 days of antiretroviral therapy
Trial: 21492926
Drug: Tuberculin skin
RxNorm normalized name: tuberculin skin test; unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculin skin test positive participants receiving continued isoniazid treatment
Trial: 21492926
Drug: Tuberculin skin
RxNorm normalized name: tuberculin skin test; unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculin skin test negative participants receiving continued isoniazid treatment
Trial: 16717465
Drug: Early tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early tirofiban administration (n = 32)
Trial: 16717465
Drug: Late tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late tirofiban administration (n = 34)
Trial: 10795728
Drug: Yohimbine (0.65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (0.65 mg/kg)
Trial: 2061566
Drug: Benfluorex (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfluorex (450 mg/day)
Trial: 6635447
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg once daily for three days
Trial: 6635447
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg plus trimethoprim 160 mg once daily for three days
Trial: 6635447
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rifampin 600 mg plus trimethoprim 160 mg
Trial: 3842545
Drug: 2 G
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 G of salt in the morning and a placebo in the evening
Trial: 3842545
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the morning and 2 G of salt in the evening
Trial: 22437792
Drug: Oral recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral recombinant salmon calcitonin (rsCT) tablets (0.2 mg/d) plus placebo nasal spray
Trial: 22437792
Drug: Synthetic salmon
RxNorm normalized name: Synthetic salmon calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic salmon calcitonin (ssCT) nasal spray (200 IU/d) plus placebo tablets
Trial: 22437792
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo tablets plus placebo nasal spray)
Trial: 22437792
Drug: Oral recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral recombinant salmon calcitonin (rsCT) tablets
Trial: 18333888
Drug: PHX1149 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHX1149 100 mg
Trial: 18333888
Drug: PHX1149 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHX1149 200 mg
Trial: 18333888
Drug: PHX1149 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHX1149 400 mg
Trial: 10371259
Drug: Alcohol day
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol day (0.35 g/kg of 95% alcohol)
Trial: 10371259
Drug: Placebo day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo day (1 ml of alcohol in 240 ml beverages)
Trial: 8877028
Drug: gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan (glu‐5‐HTP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan (glu‐5‐HTP)
Trial: 8877028
Drug: gamma‐L‐glutamyl-L‐tryptophan (glu‐TRP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma‐L‐glutamyl-L‐tryptophan (glu‐TRP)
Trial: 1673736
Drug: Continued antiepileptic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued antiepileptic treatment
Trial: 1673736
Drug: Slow withdrawal
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow withdrawal of antiepileptic treatment
Trial: 6873851
Drug: Both new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both new suppository preparations
Trial: 29503371
Drug: Facial exercises
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Facial exercises program (30 min, twice a week for 12 weeks)
Trial: 27177079
Drug: Group schema
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group schema therapy (ST)
Trial: 22377796
Drug: Black currant
RxNorm normalized name: Black currant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black currant anthocyanins (BCACs) 50 mg/day (n = 19)
Trial: 19700304
Drug: Sustained-release oral
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral oxycodone 20mg followed by immediate-release oxycodone 10mg 6-hourly for the first 24h (group O)
Trial: 19700304
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 100mug (group I)
Trial: 18355324
Drug: Saxagliptin (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin (low-dose cohort: 2.5, 5, 10, 20 or 40 mg once daily for 12 weeks)
Trial: 18355324
Drug: Saxagliptin (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin (high-dose cohort: 100 mg once daily for 6 weeks)
Trial: 1800760
Drug: Labetalol 100
RxNorm normalized name: HCTZ 25/LABETALOL 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 100 mg twice daily (n = 30)
Trial: 1800760
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 mg twice daily (n = 31)
Trial: 12529075
Drug: Caffeine (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4.0 mg/kg)
Trial: 20420475
Drug: Step‐down model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step‐down model (CP) consisting of initial short‐term day hospital treatment followed by conjoint group and individual outpatient treatment
Trial: 16062017
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg orally) followed by misoprostol (800 micro gm intravaginally)
Trial: 16062017
Drug: Methotrexate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (50 mg/m2 intramuscularly) followed by misoprostol (800 micro gm intravaginally)
Trial: 10202166
Drug: Cisplatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (40 mg/m² once a week for up to six doses during radiotherapy)
Trial: 7599666
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral bromocriptine (2.5-10.0 mg/day) during two consecutive 30-day periods (T-1 and T-2)
Trial: 7599666
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral bromocriptine (from day 1 to 15 of each 30-day period)
Trial: 7599666
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (1 and 2) after treatment
Trial: 31177924
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg rectal)
Trial: 21335941
Drug: Glycerin suppository
RxNorm normalized name: Leader Pediatric Glycerin Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin suppository (placebo)
Trial: 28947465
Drug: Continuous hyperosmolar
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperosmolar therapy (20% NaCl) plus standard care
Trial: 25032123
Drug: N‐acetyl‐cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐acetyl‐cysteine (NAC) (1200 mg/day)
Trial: 25032123
Drug: Ginseng (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng (200 mg/day)
Trial: 25032123
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antioxidant drugs)
Trial: 23424164
Drug: Mirabegron 100
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 100 mg BID
Trial: 23424164
Drug: Mirabegron 150
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 150 mg BID
Trial: 23424164
Drug: Tolterodine 4
RxNorm normalized name: tolterodine 4 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 4 mg ER
Trial: 19952809
Drug: Ibuprofen topical
RxNorm normalized name: ibuprofen topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen topical gel
Trial: 18511165
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for 4 weeks
Trial: 9201012
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention including in-hospital counseling, smoking cessation videotape, self-help literature, nicotine replacement therapy, and 3 months of telephone follow-up
Trial: 8067229
Drug: Morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine + Ephedrine
Trial: 5345935
Drug: Six-monthly chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six-monthly chest radiographs
Trial: 31743406
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution eye drops
Trial: 8706197
Drug: Edrophonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1.0 mg x kg(‐1)
Trial: 11512646
Drug: Edrophonium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.4 mg x kg(‐1)